Self-reported side effects in children and adolescents taking risperidone

Australasian Psychiatry

Volumn 18, Issue 1, 2010, Pages 42-45

  Byrne, Simon ^a   Walter, Garry ^b   Hunt, Glenn ^j   Soh, Nerissa ^c   Cleary, Michelle ^d   Duffy, Paul ^e   Crawford, Geoff ^e   Krabman, Peter ^f,g   Concannon, Patrick ^h   Malhi, Gin ⁱ  

^a Northern Sydney Central Coast Health   (Australia)

^b UNIVERSITY OF SYDNEY   (Australia)

^c Child and Adolescent Mental Health Services Australia   (Australia)

^d Research Unit   (Australia)

^e Private Practice   (Australia)

^f Chatswood NSW ^*  (Australia)

^g Child Psychiatrist in Private Practice   (Australia)

^h Private Practice   (Australia)

ⁱ UNIVERSITY OF SYDNEY   (Australia)

^j NONE

more..

Author keywords

Adolescents; Children; Liverpool University Neuroleptic Side Effect Rating Scale; Risperidone; Side effects

Indexed keywords

RISPERIDONE;

ADOLESCENT; ADULT; ARTICLE; BLURRED VISION; CHILD; CONSTIPATION; DEPRESSION; DIARRHEA; DREAMING; DRUG INDUCED HEADACHE; DRUG USE; FATIGUE; FEMALE; HUMAN; HYPERSALIVATION; MAJOR CLINICAL STUDY; MALE; MEMORY DISORDER; MOTOR DYSFUNCTION; MUSCLE SPASM; MUSCLE STIFFNESS; PATIENT ASSESSMENT; PRESCHOOL CHILD; PRESCRIPTION; PRURITUS; RESTLESSNESS; SCHOOL CHILD; SELF REPORT; SHIVERING; SIDE EFFECT; SLEEP DISORDER; SOMNOLENCE; SWEATING; TENSION; WEIGHT GAIN; WEIGHT REDUCTION; XEROSTOMIA;

ADOLESCENT; ANTIPSYCHOTIC AGENTS; CHILD; CROSS-SECTIONAL STUDIES; FEMALE; HUMANS; MALE; MENTAL DISORDERS; RISPERIDONE;

EID: 77049123035     PISSN: 10398562     EISSN: 14401665     Source Type: Journal    
DOI: 10.3109/10398560903033381     Document Type: Article

References (19)

1. Cheng-Shannon J, McGough MD, Pataki C, McCracken JT. Second-generation antipsychotic medications in children and adolescents. Journal of Child and Adolescent Psychopharmacology 2004; 14: 372-394.
2. Stahl SM. Essential Psychopharmcology - The Prescribers Guide. New York: Cambridge University Press, 2006
3. Croonenberghs J, Fegert J, Findling RL, De Smedt G, van Dongen S. Rispiridone in children with disruptive behavior disorders and subaverage intelligence. A 1-year, open-label study of 504 patients. Journal of American Academy of Child and Adolescent Psychiatry 2005; 44: 64-72.
4. Reyes M, Olah R, Csaba K, Augustyns I, Eerdekens M. Long-term safety and efficacy of risperidone in children with disruptive behaviour disorders: Results of a 2-year extension study. European Child and Adolescent Psychiatry 2005; 15: 97-104.
5. Reyes M, Croonenberghs J, Augustyns I, EerdekensLong-term use of risperidone in children with disruptive behavior disorders and subaverage intelligence: efficacy, safety and tolerability. Journal of Child and Adolescent Psychopharmacology 2006; 16: 260-272
6. Findling RL. Atypical antipsychotics in the treatment of children and adolescents. Journal of Clinical Psychiatry 2004; 65 (Suppl. 6): 3-29.
7. Olfson M, Blanco C, Liu L, Moreno C, Laje G. National trends in the outpatient treatment of children and adolescents with antipsychotic drugs. Archives of General Psychiatry 2006; 63: 679-685.
8. Silvaprasad L, Hassan T, Handy S. Survey of atypical antipsychotic medication used by children and adolescent psychiatrists. Child and Adolescent Mental Health 2006; 11: 164-167.
9. Doey T, Handelman K, Seabrook JA, Steele M. Survey of atypical antipsychotic prescribing by Canadian child psychiatrists and developmental pediatricians for patient age under 18 years. The Canadian Journal of Psychiatry. 2007; 52: 363-368.
10. Efron D, Hiscock H, Sewell JR, Cranswick NE, Vance AL, Tyl Y, Luk ESL. Prescribing of psychotropic medications for children by Australian pediatricians and child psychiatrists. Pediatrics 2003; 111: 372-375.
11. Correll CU. Metabolic side effects of second-generation antipsychotics in children and adolescents: A different story. Journal of Clinical Psychiatry 2005; 66: 1331-1332.
12. Correll CU. Endocrine and metabolic adverse effects of psychotropic medications in children and adolescents. Journal of American Academy of Child and Adolescent Psychiatry 2006; 45 :771-791.
13. Correll CU. Antipsychotic use in children and adolescents: minimizing adverse effects to maximise outcomes. Journal of American Academy of Child and Adolescent Psychiatry 2008; 47: 9-20.
14. Aman MG, Arnold E, McDougle CJ, et al. Acute and long-term safety and tolerability of risperidone in children with autism. Journal of Child and Adolescent Psychopharmacology 2005; 15: 869-884.
15. Linjaerde O, Ahlfors UG, Bech P, Dencker SJ, Elgen K. The UKU side effect rating scale. A new comprehensive rating scale for psychotropic drugs and a cross-sectional study of side effects in neuroleptic treated patients. Acta Psychiatrica Scandinavica 1987; 76: 1-100.
16. Day JC, Wood G, Dewey M, Bentall RP.. A self-rating scale for measuring neuroleptic side effects - validation in a group of schizophrenic patients. British Journal of Psychiatry 1995; 166: 650-653.
17. Lambert TJR.. Measurement of antipsychotic-induced side effects: Support for the validity of a self-report (LUNSERS) versus structured interview (UKU) approach to measurement. Human Psychopharmacology 2003; 18: 405-411.
18. Jerrell JM, McIntyre RS. Adverse events in children and adolescents treated with antipsychotic medications. Human Psychopharmacology 2008; 23: 283-290.
19. Walter G, DeLaroche A, Soh N, et al. Side effects of second generation antipsychotics: the experience, views and monitoring practices of Australian child psychiatrists. Australasian Psychiatry 2008; 16: 253-262.